{"id":"terlipressin-vasoconstrictor","safety":{"commonSideEffects":[{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Ischemic complications (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Terlipressin binds to vasopressin V1 receptors on blood vessels, triggering vasoconstriction that reduces splanchnic blood flow and portal venous pressure. This mechanism is particularly useful in portal hypertension-related conditions where elevated portal pressure drives complications such as variceal bleeding. The drug has greater V1 selectivity and longer duration of action compared to native vasopressin.","oneSentence":"Terlipressin is a vasopressin analog that selectively activates V1 receptors on vascular smooth muscle to cause vasoconstriction and reduce portal pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:35.695Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute variceal bleeding in patients with portal hypertension"},{"name":"Prevention of rebleeding from esophageal varices"},{"name":"Hepatorenal syndrome"}]},"trialDetails":[{"nctId":"NCT07178366","phase":"NA","title":"Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-05-10","conditions":"Acute-on-Chronic Liver Failure (ACLF)","enrollment":56},{"nctId":"NCT07460908","phase":"NA","title":"Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome","status":"COMPLETED","sponsor":"Lahore General Hospital","startDate":"2025-05-01","conditions":"Hepatorenal Syndrome","enrollment":60},{"nctId":"NCT05490888","phase":"PHASE1","title":"Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics","status":"RECRUITING","sponsor":"PharmaIN","startDate":"2022-01-03","conditions":"Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic","enrollment":74},{"nctId":"NCT06556472","phase":"NA","title":"Safety and Efficacy of Continuous Infusion of Terlipressin With Norepinephrine Versus Norepinephrine Alone in Improving Outcomes of Acute Kidney Injury in Acute on Chronic Liver Failure With Septic Shock","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2024-08-15","conditions":"Acute on Chronic Liver Failure","enrollment":126},{"nctId":"NCT05315557","phase":"NA","title":"Efficacy and Safety of Vasopressin Versus Terlipressin as a Second Vasopressor in Critically Ill Cirrhotics With Septic Shock- the VITEL-C Trial","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2022-04-05","conditions":"Septic Shock, Cirrhosis, Liver","enrollment":100},{"nctId":"NCT04339868","phase":"PHASE2","title":"Terlipressin for Refractory Septic Shock","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2020-04-03","conditions":"Septic Shock, Refractory Shock, Norepinephrine Adverse Reaction","enrollment":130},{"nctId":"NCT03038503","phase":"PHASE3","title":"What Should be the Next Vasopressor for Severe Septic Shock? Methylene Blue or Terlipressin","status":"UNKNOWN","sponsor":"Ramathibodi Hospital","startDate":"2016-12","conditions":"Septic Shock, Refractory Shock","enrollment":60},{"nctId":"NCT02468063","phase":"NA","title":"To Assess the Efficacy of Early Introduction of a Combination of Low Dose Vasopressin Analogue in Addition to Noradrenaline as a Vasopressor in Patients of Cirrhosis With Septic Shock","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2015-05-01","conditions":"Cirrhosis With Septic Shock","enrollment":184},{"nctId":"NCT01112852","phase":"PHASE4","title":"EVL (Endoscopic Variceal Ligation) Plus Vasoconstrictor vs.Ligation Plus PPI( Proton Pump Inhibitor) in the Control of Acute Esophageal Variceal Bleeding","status":"COMPLETED","sponsor":"National Science and Technology Council, Taiwan","startDate":"2006-12","conditions":"Esophageal Varices, Bleeding","enrollment":118},{"nctId":"NCT00863837","phase":"PHASE4","title":"Prevention of Esophageal Variceal Rebleeding","status":"UNKNOWN","sponsor":"National Science and Technology Council, Taiwan","startDate":"2006-12","conditions":"Esophageal Variceal Rebleeding","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":144,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["vasoconstrictor"],"phase":"marketed","status":"active","brandName":"terlipressin (vasoconstrictor)","genericName":"terlipressin (vasoconstrictor)","companyName":"National Science and Technology Council, Taiwan","companyId":"national-science-and-technology-council-taiwan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Terlipressin is a vasopressin analog that selectively activates V1 receptors on vascular smooth muscle to cause vasoconstriction and reduce portal pressure. Used for Acute variceal bleeding in patients with portal hypertension, Prevention of rebleeding from esophageal varices, Hepatorenal syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}